GKOS241220C70000
- 0.00
- 0.000.00%
Glaukos Newsroom
Glaukos Seeks FDA Approval for Non-Invasive Keratoconus Therapy Epioxa
Express News | Glaukos Submits New Drug Application to U.S. FDA for Epioxa™
The Three-year Returns Have Been Stellar for Glaukos (NYSE:GKOS) Shareholders Despite Underlying Losses Increasing
Is Glaukos (NYSE:GKOS) Weighed On By Its Debt Load?
Stifel Maintains Glaukos(GKOS.US) With Buy Rating, Maintains Target Price $153
NYSE New 52-Week Highs And Lows
Glaukos (GKOS) Receives a Buy From Stifel Nicolaus
Glaukos Is Maintained at Buy by Truist Securities
Truist Financial Maintains Glaukos(GKOS.US) With Buy Rating, Announces Target Price $185
Glaukos Price Target Raised to $185 From $152 at Truist
Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
Express News | Glaukos Corp : Jefferies Raises Target Price to $160 From $155
Insider Sale: Director at $GKOS (GKOS) Sells 2,000 Shares
J.P. Morgan Maintains Glaukos(GKOS.US) With Buy Rating, Raises Target Price to $160
Glaukos (GKOS) Receives a Buy From J.P. Morgan
Wells Fargo Maintains Overweight on Glaukos, Raises Price Target to $153
Here's Why You Should Add Glaukos Stock to Your Portfolio Now
Glaukos Raised to Buy From Neutral by Citigroup
Glaukos Price Target Raised to $162.00/Share From $132.00 by Citigroup
Wells Fargo Maintains Glaukos(GKOS.US) With Buy Rating, Raises Target Price to $153